
-
Asian stocks rise as China-US trade talks boost optimism
-
Toxic mushroom victim said meal was 'delicious', Australian court hears
-
China's Xi heads to Moscow to beef up 'no limits' Putin partnership
-
World energy methane emissions near record high in 2024: IEA
-
White smoke: signalling a new pope down the ages
-
What's a cardinal? The 'princes' of the Church electing a new pope
-
Papal conclave by the numbers
-
The Vatican: a papal powerhouse, world's smallest state
-
Trump, Ukraine propel EU and UK towards defence pact
-
Syrian leader to meet Macron in first European visit
-
History beckons as cardinals gather to elect new pope
-
China's Xi aims to beef up 'no limits' Putin partnership
-
Hit by Trump cuts, journalists at Dubai-based US channel face uncertain future
-
Roglic gunning for Giro as Pogacar's absence leaves door open
-
Trump's White House creates own media universe
-
Sotheby's postpones historical gems auction after India backlash
-
Taiwan bicycle makers in limbo as US tariff threat looms
-
Tobacco town thrives as China struggles to kick the habit
-
Venezuelan opposition figures 'rescued', now in US: Rubio
-
China eases monetary policy to boost ailing economy
-
Haliburton stunner sinks Cavs as Pacers take 2-0 series lead
-
No rate cuts expected from US Fed facing 'unfavorable' conditions
-
'No one is illegal': Mormon women stage patchwork protest in Washington
-
Indonesia's silvermen beg to make ends meet
-
Toronto festival head says Trump tariffs would hurt film quality
-
Trump talks tough on China, but early focus elsewhere
-
China vows to defend 'justice' in looming trade talks with US
-
Man Utd seek to finish off Athletic Bilbao in chase for Europa glory
-
AP to continue crediting 'Napalm Girl' photo to Nick Ut after probe
-
Wallace MacDonald Holdings (WMH) Ignites a New Era of American Manufacturing with Revolutionary "Made in America" Technology Complex in Nevada
-
HigherKey Studios Set to Redefine Entertainment, Technology, and Human-Centered Innovation
-
Sportstech Provides April 2025 and LTM Business Performance Update Ahead of China Sport Show and TRNR Acquisition Close
-
Tocvan Discovers Another Near Surface High-Grade Corridor at Gran Pilar Gold - Silver Project Drills 6.1 meters of 5.4 g/t Gold and 39 g/t Silver within 41.2 meters of 1.0 g/t Gold and 10 g/t Silver
-
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
-
Colombia moves to join China's Belt and Road
-
Martinez cried 'for two days' after nearly missing Barca triumph with injury
-
US, Chinese officials to hold trade talks in Switzerland
-
Barca 'will be back' after painful Champions League exit to Inter, says Flick
-
US jury awards WhatsApp $168 mn in NSO Group cyberespionage suit
-
India launches strikes on Pakistan, Islamabad vows to 'settle the score'
-
Trump vows 'seamless' experience for 2026 World Cup fans
-
Motown legend Smokey Robinson sued for sexual assault
-
Trump hopes India-Pakistan clashes end 'very quickly'
-
Frattesi shoots Inter into Champions League final after Barcelona epic
-
India launches strikes on Pakistan, Islamabad vows retaliation
-
India launches strikes on Pakistan as Islamabad vows retaliation
-
Alpine shock as F1 team principal Oakes resigns
-
Merz elected German chancellor after surprise setback
-
Gujarat edge Mumbai in last-ball thriller to top IPL table
-
Israel's plan for Gaza draws international criticism

US health experts vote against MDMA as treatment for PTSD
A panel of US health experts convened by the Food and Drug Administration on Tuesday overwhelmingly voted against the use of MDMA, commonly known as ecstasy, to treat post-traumatic stress disorder.
PTSD, a debilitating mental health condition that develops after a person experiences or is threatened by traumatic events such as death, combat or sexual assault, affects an estimated five percent of Americans in any given year.
But pharmaceutical treatment options are so far limited to two antidepressants that require three months of dosing to take effect, and response rates to the medications have been found to be uneven.
California-based Lykos Therapeutics has based its request for regulatory approval on two clinical studies, each of which enrolled around 100 people, to evaluate MDMA used together with other psychological interventions such as talk therapy, against a placebo with talk therapy.
These two studies, published in the prestigious journal Nature Medicine, indicated MDMA was indeed both safe and highly effective at treating PTSD.
But nine out of 11 experts on the panel said available data was not enough to show the treatment was effective, and 10 out of 11 said the benefits did not outweigh the risks.
"I think this is a really exciting treatment. I'm really encouraged by the results to date," said one of the experts, Paul Holtzheimer of the National Center for PTSD.
"But I feel that both from an efficacy and a safety standpoint, it is still premature."
The vote by the panel of experts is non-binding, but the FDA rarely goes against their recommendations.
- Not enough side effect data -
MDMA -- methylenedioxymethamphetamine -- is a Schedule 1 drug under the Controlled Substances Act, and approving it for medical use would have represented a major shift.
In a briefing document put together ahead of the meeting, FDA staff raised concerns that although the studies were nominally "double-blinded" -- meaning neither those being tested nor their health care workers knew who received the treatment versus the placebo -- most people were able to accurately guess what they received.
This "functional unblinding," they argued, introduces bias and uncertainty into study outcomes.
FDA staff also criticized Lykos for not gathering sufficient side effect data, including whether participants experienced "euphoria" or "elated mood," which, they argued, "would be informative for an assessment of abuse potential or characterization of anticipated effects of the drug."
Reports from recreational use suggest MDMA has harmful impacts on heart and liver health -- but the company did not gather enough data in these areas, the FDA said.
- Research misconduct allegations -
Then there were troubling allegations of research impropriety linked to the trials that surfaced in a draft report by the nonprofit Institute for Clinical and Economic Review.
These include claims that the trials "pulled heavily from the existing community of those interested and involved in the use of psychedelics for possible psychological benefits."
Some patients told the nonprofit they were allegedly prevented from entering the long term-follow up study "and felt this was done to keep these negative outcomes out of the data set."
"We certainly take those allegations very seriously and are quite concerned by them," the FDA's Tiffany Farchione said during the meeting, adding a probe was ongoing.
Lykos has said a final decision from the FDA on authorization should come by mid-August.
If the agency were to authorize the treatment over the advisory panel's objections, there could be certain strict stipulations attached -- for example, that the drug only be dispensed in health care settings, with subjects carefully monitored and enrolled in a registry to document side effects.
A.Malone--AMWN